On August 17, AKESO fell 3.49% in regular trading, trading at 91.0 HKD/share, with turnover of HKD 175 million. The decline reflects sustained profit-taking pressure following the company's announcement on August 12 that its core product ivonescimab received NMPA approval for a third indication.

The approval covers ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer, based on positive results from the Phase III HARMONi-6 study comparing it against tislelizumab plus chemotherapy. This marks the third approved indication since the molecule's initial authorization in May 2024. However, the positive catalyst had already driven eight consecutive days of gains prior to the formal approval, creating significant profit-taking overhang once the news materialized.

Within the Biotechnology sector, performance was mixed. Among individual stocks, BEONE MEDICINES up 0.28%, INNOVENT BIO up 0.21%, LEADS BIOLABS-B up 1.84%, REMEGEN down 1.43%, EVEREST MED down 4.44%. AKESO's decline reflects the classic pattern of funds exiting after a major catalyst is fully priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)